Journal article : Review
Therapeutic strategies for congenital myasthenic syndromes
- Abstract:
-
To date, more than 25 genes have been implicated in the etiology of the congenital myasthenic syndromes (CMS), and an ever-growing phenotypic landscape is now encountered in the CMS clinic. Unlike the autoimmune form of myasthenia, there is no role for immunomodulatory agents in the treatment of CMS. The present-day drug repertoire comprises acetylcholinesterase inhibitors (mainly pyridostigmine), 3,4-diaminopyridine (3,4-DAP), ephedrine, salbutamol/albuterol, open-channel blockers (fluoxetin...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- Annals of the New York Academy of Sciences Journal website
- Volume:
- 1412
- Issue:
- 1
- Pages:
- 129-136
- Place of publication:
- United States
- Publication date:
- 2018-01-30
- Acceptance date:
- 2017-10-02
- DOI:
- EISSN:
-
1749-6632
- ISSN:
-
0077-8923
- Pmid:
-
29381222
Item Description
- Language:
- English
- Keywords:
- Subtype:
- Review
- Pubs id:
-
823455
- Local pid:
- pubs:823455
- Deposit date:
- 2020-02-17
Terms of use
- Copyright holder:
- New York Academy of Sciences
- Copyright date:
- 2018
- Rights statement:
- © 2017 New York Academy of Sciences.
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record